Summary
Signal counts
Assets tracked: 3
Watchlist assets: 3
Registry stop assets: 0
Sponsor overview
University of California, San Francisco
Public clinical-program risk signals across linked oncology Phase 2 assets for this sponsor.
Evidence links
Public sources
https://clinicaltrials.gov/study/NCT03933670 | https://clinicaltrials.gov/study/NCT05746208 | https://clinicaltrials.gov/study/NCT01136967 | https://clinicaltrials.gov/study/NCT01111461 | https://clinicaltrials.gov/study/NCT06252675 | https://clinicaltrials.gov/study/NCT01414855
Assets
Linked programs
- Hyperpolarized Carbon C 13 Pyruvate: Watchlist Signal (2/5)
- Lenvatinib: Operational Burden Signal (2/5)
- Obinutuzumab: Operational Burden Signal (2/5)